Farxiga approved in the US for the treatment of heart failure in patients with heart failure with reduced ejection fraction
Farxiga is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalisation for heart failureAstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). The approval by the Food and Drug Administration (FDA) was based on positive results from the landmark Phase III DAPA-HF trial, which showed Farxiga achieving a statistically